Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ERB-257 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects
Latest Information Update: 08 May 2014
At a glance
- Drugs ERB 257 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors Wyeth
- 08 May 2014 New trial record